Effect of levosimendan on E/E' ratio in patients with ischemic heart failure

Basit Öğe Kaydı
dc.contributor.authorDuygu, Hamza
dc.contributor.authorOzerkan, Filiz
dc.contributor.authorNalbantgil, Sanem
dc.contributor.authorZoghi, Mehdi
dc.contributor.authorAkilli, Azem
dc.contributor.authorAkin, Mustafa
dc.contributor.authorNazli, Cem
dc.contributor.authorErgene, Oktay
dc.date.accessioned2019-10-27T19:55:49Z
dc.date.available2019-10-27T19:55:49Z
dc.date.issued2008
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground: Levosimendan is a novel positive inotropic calcium sensitizer agent used in acute heart failure. In acute heart failure, it improves hemodynamic parameters more favorably than the conventional positive inotropes. In this study, the effect levosimendan on E/E' ratio as a non-invasive indicator of LV filling pressure was evaluated compared to dobutamine in a prospective, randomized, patient-blind manner. Methods: Patients with an LVEF < 40% admitting with acute heart failure attack with ischemic origin were included to this study. Patients were randomized to levosimendan (n=30, mean age: 64 +/- 10 years, 63% male) or dobutamine (n=32, mean age: 66 +/- 8 years, 54% male) groups. The ratio of the peak E wave velocity taken from mitral inflow with PW Doppler to the peak E' wave velocity taken from mitral lateral annulus with tissue Doppler was determined. Pre-treatment and 24-hour after the treatment E/E' ratios were calculated and then compared in both groups. Results: Age, gender, concomitant medications were similar in both groups ( p > 0.05). There was no difference for pre-treatment baseline E/E' ratios between levosimendan and dobutamine groups (15.7 +/- 4.0 vs 15.2 +/- 7.5 respectively, p=0.1). There were significant reductions in post-treatment E/E' ratios in levosimendan ( 15.7 +/- 4.0 vs 9.3 +/- 2.8, p=0.01) and dobutamine groups ( 15.2 +/- 7.5 vs 12.9 +/- 5.6, p=0.04). However, the reduction in levosimendan group was greater compared to dobutamine group (p=0.01). Conclusions: Levosimendan causes a greater reduction of E/E' ratio compared to dobutamine in acute systolic left heart failure. This may explain the more favorable hemodynamic effects of levosimendan when compared to conventional positive inotropics in patients with systolic left heart failure. (c) 2007 Elsevier Ireland Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.ijcard.2006.11.145en_US
dc.identifier.endpage203en_US
dc.identifier.issn0167-5273
dc.identifier.issue2en_US
dc.identifier.pmid17316845en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage201en_US
dc.identifier.urihttps://doi.org/10.1016/j.ijcard.2006.11.145
dc.identifier.urihttps://hdl.handle.net/11454/40737
dc.identifier.volume123en_US
dc.identifier.wosWOS:000252154900030en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Ireland Ltden_US
dc.relation.ispartofInternational Journal of Cardiologyen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectlevosimendanen_US
dc.subjectdobutamineen_US
dc.subjectischemic heart failureen_US
dc.subjectE/E' ratioen_US
dc.titleEffect of levosimendan on E/E' ratio in patients with ischemic heart failureen_US
dc.typeLetteren_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu